While many companies have forayed into the marijuana industry, few have made it to the global arena. Bedrocan Cannabis Corp is a worldwide leader in medicinal cannabis production. With a long industry record, this Canada-based outfit produces strains used in seven countries by more than 15,000 patients. It is the only source of legally exported cannabis across the globe, and one of only two global suppliers of pharmaceutical cannabis.
The company’s long history began in 1984. Back then, it was growing vegetables indoors in the Netherlands and was known as Bedrocan BV. Acquiring a federal license in the 1990s, it began cultivating medical cannabis, and in 2011, it began conversations with Canadian authorities. Not long after that, the company created Bedrocan Canada.
Today, Bedrocan Canada is listed in the TSXV market as BED and is valued at CAD 38.25 M.
The company now provides five cannabis varieties, each with a specific formulation of the medicinal cannabis compounds cannabidiol (CBD) and tetrahydrocannabinol (THC). These strains are used to treat patients with health conditions like chronic pain, arthritis, depression, anxiety, and epilepsy.
Bedrocan Canada’s marijuana varieties are imported from the Netherlands and then sold in Canada at a per-gram flat rate. The company, however, is aiming to locally produce marijuana in Canada starting 2015.
With a big focus on research, the Bedrocan family is ISO 9001-rated, indicating its competence as a supplier. It is also a partner of government agencies such as the Dutch Ministry of Health, Welfare, and Sport in conducting marijuana research and projects.
Bedrocan’s top people are CEO and President Marc Wayne; CFO Michael Singer; COO H. Hamish Sutherland; and Chief Production Officer and Bedrocan BV CEO Tjalling Erkelens.
Yahoo! Finance: BED.V News
Latest Financial News for BED.V